1. Home
  2. TIL vs SNCR Comparison

TIL vs SNCR Comparison

Compare TIL & SNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • SNCR
  • Stock Information
  • Founded
  • TIL 2018
  • SNCR 2000
  • Country
  • TIL United States
  • SNCR United States
  • Employees
  • TIL N/A
  • SNCR N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • SNCR EDP Services
  • Sector
  • TIL Health Care
  • SNCR Technology
  • Exchange
  • TIL Nasdaq
  • SNCR Nasdaq
  • Market Cap
  • TIL 230.1M
  • SNCR 87.5M
  • IPO Year
  • TIL 2021
  • SNCR 2006
  • Fundamental
  • Price
  • TIL $24.49
  • SNCR $7.65
  • Analyst Decision
  • TIL Buy
  • SNCR Strong Buy
  • Analyst Count
  • TIL 5
  • SNCR 1
  • Target Price
  • TIL $119.00
  • SNCR $13.00
  • AVG Volume (30 Days)
  • TIL 310.3K
  • SNCR 142.2K
  • Earning Date
  • TIL 08-12-2025
  • SNCR 08-05-2025
  • Dividend Yield
  • TIL N/A
  • SNCR N/A
  • EPS Growth
  • TIL N/A
  • SNCR N/A
  • EPS
  • TIL N/A
  • SNCR N/A
  • Revenue
  • TIL N/A
  • SNCR $172,842,000.00
  • Revenue This Year
  • TIL N/A
  • SNCR $2.07
  • Revenue Next Year
  • TIL N/A
  • SNCR $5.42
  • P/E Ratio
  • TIL N/A
  • SNCR N/A
  • Revenue Growth
  • TIL N/A
  • SNCR 4.64
  • 52 Week Low
  • TIL $9.70
  • SNCR $6.00
  • 52 Week High
  • TIL $92.00
  • SNCR $15.46
  • Technical
  • Relative Strength Index (RSI)
  • TIL 47.69
  • SNCR 55.94
  • Support Level
  • TIL $21.80
  • SNCR $7.10
  • Resistance Level
  • TIL $26.91
  • SNCR $7.97
  • Average True Range (ATR)
  • TIL 3.52
  • SNCR 0.42
  • MACD
  • TIL -0.37
  • SNCR 0.17
  • Stochastic Oscillator
  • TIL 35.14
  • SNCR 75.63

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About SNCR Synchronoss Technologies Inc.

Synchronoss Technologies Inc is a provider of white-label cloud, messaging, digital and network management solutions that enable its customers to keep subscribers, systems, networks and content in sync. The Synchronoss Personal CloudTM solution is designed to create an engaging and trusted customer experience through ongoing content management and engagement. The Synchronoss Personal CloudTM platform is a secure and scalable, white-label platform that allows its customers' subscribers to backup and protect, engage with, and manage their personal content. The company derives revenue from subscriptions and transaction-based fees. A majority of the firm's revenue is generated in the United States, and the rest is from countries across the world.

Share on Social Networks: